U.S. patent application number 17/414285 was filed with the patent office on 2022-03-10 for ursodeoxycholic acid-containing agent for treating or preventing presbyopia.
This patent application is currently assigned to SANTEN PHARMACEUTICAL CO., LTD.. The applicant listed for this patent is SANTEN PHARMACEUTICAL CO., LTD.. Invention is credited to Masatomo KATO, Kazutaka KIDO, Tomoko ODA.
Application Number | 20220072012 17/414285 |
Document ID | / |
Family ID | |
Filed Date | 2022-03-10 |
United States Patent
Application |
20220072012 |
Kind Code |
A1 |
KATO; Masatomo ; et
al. |
March 10, 2022 |
URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING
PRESBYOPIA
Abstract
The present disclosure provides an agent for treating or
preventing eye diseases such as presbyopia, comprising, as an
active ingredient, ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof.
Inventors: |
KATO; Masatomo; (Nara,
JP) ; ODA; Tomoko; (Nara, JP) ; KIDO;
Kazutaka; (Osaka, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SANTEN PHARMACEUTICAL CO., LTD. |
Osaka |
|
JP |
|
|
Assignee: |
SANTEN PHARMACEUTICAL CO.,
LTD.
Osaka
JP
|
Appl. No.: |
17/414285 |
Filed: |
December 17, 2019 |
PCT Filed: |
December 17, 2019 |
PCT NO: |
PCT/JP2019/049352 |
371 Date: |
June 15, 2021 |
International
Class: |
A61K 31/575 20060101
A61K031/575; A61K 9/00 20060101 A61K009/00; A61P 27/10 20060101
A61P027/10 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 18, 2018 |
JP |
2018-236717 |
Claims
1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. A method for treating or preventing presbyopia, comprising
administering to a subject in need thereof an effective amount of
ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid,
or an ester thereof, or a pharmaceutically acceptable salt
thereof.
14. The method according to claim 13, wherein the ursodeoxycholic
acid or an amide conjugate of ursodeoxycholic acid, or an ester
thereof, or a pharmaceutically acceptable salt thereof, is
administered ophthalmically.
15. The method according to claim 13, wherein the ursodeoxycholic
acid or an amide conjugate of ursodeoxycholic acid, or an ester
thereof, or a pharmaceutically acceptable salt thereof, is
administered as an eye drop or an eye ointment.
16. The method according to claim 15, wherein the amount of
ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid,
or an ester thereof, or a pharmaceutically acceptable salt thereof,
comprised in the eye drop or the eye ointment is 0.00001 to 10%
(w/v).
17. The method according to claim 13, wherein the ursodeoxycholic
acid or an amide conjugate of ursodeoxycholic acid, or an ester
thereof, or a pharmaceutically acceptable salt thereof, is selected
from ursodeoxycholic acid, tauroursodeoxycholic acid,
glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester,
ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl
ester, ursodeoxycholic acid isopropyl ester, ursodeoxycholic acid
n-butyl ester, ursodeoxycholic acid isobutyl ester, ursodeoxycholic
acid sec-butyl ester, ursodeoxycholic acid tent-butyl ester,
ursodeoxycholic acid n-pentyl ester, ursodeoxycholic acid n-hexyl
ester, or a pharmaceutically acceptable salt thereof.
18. The method according to claim 13, wherein the ursodeoxycholic
acid or an amide conjugate of ursodeoxycholic acid, or an ester
thereof, or a pharmaceutically acceptable salt thereof, is selected
from ursodeoxycholic acid, tauroursodeoxycholic acid,
glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester,
ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl
ester, ursodeoxycholic acid isopropyl ester, or a pharmaceutically
acceptable salt thereof.
19. The method according to claim 13, wherein the ursodeoxycholic
acid or an amide conjugate of ursodeoxycholic acid, or an ester
thereof, or a pharmaceutically acceptable salt thereof, is
ursodeoxycholic acid or a sodium salt thereof.
20. The method according to claim 15, wherein the eye drop or the
eye ointment comprises water, and an additive selected from ethyl
pyruvate, sodium dihydrogenphosphate monohydrate, disodium
hydrogenphosphate, hydroxypropyl methylcellulose, NaCl, or a
mixture thereof.
21. A method for treating or preventing an eye disease accompanied
by a decrease in lens elasticity, comprising administering to a
subject in need thereof an effective amount of ursodeoxycholic acid
or an amide conjugate of ursodeoxycholic acid, or an ester thereof,
or a pharmaceutically acceptable salt thereof.
22. A method for treating or preventing an eye disease accompanied
by a decrease in accommodative function of the eye, comprising
administering to a subject in need thereof an effective amount of
ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid,
or an ester thereof, or a pharmaceutically acceptable salt thereof.
Description
TECHNICAL FIELD
[0001] The present invention relates to an agent for treating or
preventing presbyopia, comprising ursodeoxycholic acid or an amide
conjugate of ursodeoxycholic acid, or an ester thereof, or a
pharmaceutically acceptable salt thereof as an active
ingredient.
BACKGROUND ART
[0002] Presbyopia is one of aging phenomena of the eye that begins
around the age of 40 and is commonly called aged eyes. According to
Non-Patent Document 1, presbyopia is defined as a disease state in
which the accommodative amplitude decreases with aging (Age-Related
Loss of Accommodation). In order to focus on something near or far
away, it is necessary for the light that enters the eye to be
refracted appropriately as it passes through the lens. Therefore,
the eye has the function of adjusting the thickness of the lens
such as contraction of the ciliary muscle located near the lens.
The ocular tissues involved in the accommodation include lens,
Zinn's zonule, lens capsule, and ciliary muscle. However, if the
function of the ciliary muscle deteriorates due to aging, or if the
lens elasticity (or, viscoelasticity) deteriorates, that is, the
lens hardens, it becomes difficult to adjust the thickness of the
lens, and it becomes difficult to focus on objects. This condition
is presbyopia.
[0003] Reading glasses have been used to cope with presbyopia, but
there are recent reports of research and development of therapeutic
agents for presbyopia. For example, Patent Document 1 discloses
that lipoic acid derivatives such as lipoic acid choline ester
(alias, EV06, UNR844) are useful for the treatment of presbyopia.
And an eye drop comprising lipoic acid choline ester is under
clinical development in the United States. Clinical developments of
the treatment of presbyopia are also underway for an eye drop
comprising AGN-199201 and AGN-190584, an eye drop comprising
PRX-100, and an eye drop comprising PresbiDrops (CSF-1). However,
the condition of patients with presbyopia is diverse, and an
increase in the types of therapeutic agents for eye diseases is
still strongly desired so that therapeutic agents can be selected
accordingly.
[0004] Ursodeoxycholic acid is a compound that promotes bile
secretion and inhibits cytokine/chemokine production, and is
therefore used in the treatment of liver diseases (Non-Patent
Document 2). However, there is no literature reporting relationship
between ursodeoxycholic acid and presbyopia treatment.
PRIOR ART DOCUMENT
Patent Document
[0005] Patent Document 1: WO 2010/147957
Non-Patent Document
[0006] Non-Patent Document 1: "Atarashii ganka" [A New
Ophthalmology], Vol. 28, No. 7, 985-988, 2011
[0007] Non-Patent Document 2: Urso.RTM. Tablets 50 mg Urso.RTM.
Tablets 100 mg Package insert
[0008] The disclosures of the prior art documents cited herein are
hereby incorporated by reference in their entirety.
SUMMARY
Technical Problem
[0009] An object of the present application is to provide a new
measure for treating or preventing presbyopia, which is a very
interesting challenge.
Solution to Problem
[0010] As a result of intensive research to solve the above
problem, the present inventors have found that ursodeoxycholic acid
surprisingly improves lens elasticity, and thereby have reached the
present application.
[0011] Specifically, the present disclosure provides the following
aspects of the invention. [0012] [1] An agent for treating or
preventing presbyopia comprising, as an active ingredient,
ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid,
or an ester thereof, or a pharmaceutically acceptable salt thereof.
[0013] [2] An agent for treating or preventing an eye disease
accompanied by a decrease in lens elasticity comprising, as an
active ingredient, ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof. [0014] [3] The agent according to [2],
wherein the eye disease is accompanied by a decrease in
accommodative function of the eye [0015] [4] An agent for treating
or preventing an eye disease accompanied by a decrease in
accommodative function of the eye comprising, as an active
ingredient, ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof. [0016] [5] The agent according to any one
of [2] to [4], wherein the eye disease is presbyopia. [0017] [6]
The agent according to any one of [1] to [5], wherein the agent is
for ophthalmic administration. [0018] [7] The agent according to
any one of [1] to [6], wherein the agent is an eye drop or an eye
ointment. [0019] [8] The agent according to any one of [1] to [7],
wherein the amount of ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof comprised in the agent is 0.00001 to 10%
(w/v). [0020] [9] The agent according to any one of [1] to [8],
comprising ursodeoxycholic acid, tauroursodeoxycholic acid,
glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester,
ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl
ester, ursodeoxycholic acid isopropyl ester, ursodeoxycholic acid
n-butyl ester, ursodeoxycholic acid isobutyl ester, ursodeoxycholic
acid sec-butyl ester, ursodeoxycholic acid tert-butyl ester,
ursodeoxycholic acid n-pentyl ester, ursodeoxycholic acid n-hexyl
ester, or a pharmaceutically acceptable salt thereof. [0021] [10]
The agent according to any one of [1] to [9], comprising
ursodeoxycholic acid, tauroursodeoxycholic acid,
glycoursodeoxycholic acid, ursodeoxycholic acid methyl ester,
ursodeoxycholic acid ethyl ester, ursodeoxycholic acid n-propyl
ester, ursodeoxycholic acid isopropyl ester, or a pharmaceutically
acceptable salt thereof. [0022] [11] The agent according to any one
of [1] to [10], comprising ursodeoxycholic acid or a sodium salt
thereof. [0023] [12] The agent according to any one of [1] to [11],
further comprising water, and an additive selected from ethyl
pyruvate, sodium dihydrogenphosphate monohydrate, disodium
hydrogenphosphate, hydroxypropyl methylcellulose, NaCl, and a
mixture thereof. [0024] [13] Use of ursodeoxycholic acid or an
amide conjugate of ursodeoxycholic acid, or an ester thereof, or a
pharmaceutically acceptable salt thereof, in the manufacture of an
agent for treating or preventing presbyopia, an eye disease
accompanied by a decrease in lens elasticity, or an eye disease
accompanied by a decrease in accommodative function of the eye.
[0025] [14] Ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof, for use in the treatment or prevention of
presbyopia, an eye disease accompanied by a decrease in lens
elasticity, or an eye disease accompanied by a decrease in
accommodative function of the eye. [0026] [15] A method for
treating or preventing presbyopia, an eye disease accompanied by a
decrease in lens elasticity, or an eye disease accompanied by a
decrease in accommodative function of the eye, comprising
administering to a subject in need thereof an effective amount of
ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid,
or an ester thereof, or a pharmaceutically acceptable salt
thereof.
[0027] Each of the elements described in the above [1] to [15] may
be optionally selected and combined.
Advantageous Effects of Invention
[0028] The therapeutic or prophylactic agent of the present
disclosure can improve the lens elasticity, which is important for
lens thickness adjustment, and is therefore useful in the treatment
or prevention of eye diseases such as presbyopia etc.
Description of Embodiments
[0029] Embodiments of the present invention are described in detail
below.
[0030] The present disclosure provides an agent for treating or
preventing presbyopia comprising, as an active ingredient,
ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid,
or an ester thereof, or a pharmaceutically acceptable salt thereof
(hereinafter sometimes referred to as "the agent of the present
invention"). The agent of the present invention may be used to
improve lens elasticity. In addition, the agent of the present
invention may be used to improve eye accommodation.
[0031] Ursodeoxycholic acid is a compound represented by formula
(1):
##STR00001##
(CAS Registration Number: 128-13-2)), also called ursodiol and
3.alpha.,7.beta.-Dihydroxy-5.beta.-cholan-24-oic acid, and
sometimes abbreviated as UDCA.
[0032] The amide conjugates of ursodeoxycholic acid which may be
comprised in the agent of the present invention refer to amide
conjugates having a --CO--NH-- bond which is formed by dehydration
condensation of the carboxyl group of ursodeoxycholic acid with an
amino group of an amino compound.
[0033] Examples of such amino compound include:
[0034] amino acids: for example, alanine, leucine, arginine,
lysine, asparagine, methionine, aspartic acid, phenylalanine,
cysteine, glutamine, serine, glutamic acid, threonine, glycine,
tryptophan, histidine, tyrosine, isoleucine, and valine;
[0035] 2-aminoadipic acid, 3-aminoadipic acid, 2-aminobutanoic
acid, 4-aminobutanoic acid, 2,4-diaminobutanoic acid,
2-aminohexanoic acid, 6-aminohexanoic acid, 1i-alanine,
2-aminopentanoic acid, 2,3-diaminopropanoic acid, 2-aminopimelic
acid, 2,6-diaminopimelic acid, cysteic acid, 2,4-diaminobutanoic
acid, 2,6-diaminopimelic acid, 2,3-diaminopropanoic acid,
4-carboxyglutamic acid, homocysteine, homoserine, homoserine
lactone, homoserine lactone, 5-hydroxylysine, allohydroxylysine,
alloisoleucine, norleucine, norvaline, ornithine, allothreonine,
and thyroxine;
[0036] amino acid analogs: e.g., taurine.
[0037] Examples of the amide conjugates of ursodeoxycholic acid
include tauroursodeoxycholic acid and glycoursodeoxycholic
acid.
[0038] Tauroursodeoxycholic acid is a compound represented by
formula (2):
##STR00002##
[0039] (CAS Registration Number: 14605-22-2), also called
3.alpha.,7.beta.-Dihydroxy-5.beta.-cholan-24-oic Acid
N-(2-Sulfoethyl)amide, and sometimes abbreviated as TUDCA.
[0040] Glycoursodeoxycholic acid is a compound represented by
formula (3):
##STR00003##
[0041] (CAS Registration Number: 64480-66-6), also called
N-(3.alpha.,7.beta.-Dihydroxy-5(3-cholan-24-oyl)glycine, and
sometimes abbreviated as GUDCA.
[0042] Examples of the esters of ursodeoxycholic acid which may be
comprised in the agent of the present invention include esters
which are formed by dehydration condensation of the carboxyl group
of ursodeoxycholic acid with a monohydric alcohol having 1 to 6
carbon atoms (preferably 1 to 4 carbon atoms, more preferably 1 to
3 carbon atoms).
[0043] Examples of the esters of the amide conjugates of
ursodeoxycholic acid which may be comprised in the agent of the
present invention include, for example, when the amino compound
part has carboxyl group(s) and/or sulfonic acid group(s), esters
which are formed by dehydration condensation of the carboxyl
group(s) and/or the sulfonic acid group(s) with monohydric
alcohol(s) having 1 to 6 carbon atoms (preferably 1 to 4 carbon
atoms, more preferably 1 to 3 carbon atoms).
[0044] Specific Examples of the esters of ursodeoxycholic acid or
the esters of amide conjugates of ursodeoxycholic acid include
methyl esters, ethyl esters, n-propyl esters, isopropyl esters,
n-butyl esters, isobutyl esters, sec-butyl esters, tert-butyl
esters, n-pentyl esters, and n-hexyl esters. Preferred examples of
the ester include methyl esters, ethyl esters, n-propyl esters, and
isopropyl esters.
[0045] Other examples include carboxylic acid esters which are
formed by dehydration condensation of at least one hydroxyl group
of ursodeoxycholic acid or an amide conjugate of ursodeoxycholic
acid with a carboxylic acid having 1 to 6 carbon atoms (preferably
1 to 4 carbon atoms, more preferably 2 to 3 carbon atoms). Specific
examples of the carboxylic acid esters include formate esters,
acetate esters, propionate esters, isopropionate esters, butyrate
esters, isobutyrate esters, pivalate esters, valerate esters, or
isovalerate esters. Preferred examples of the carboxylic acid
esters include acetate esters.
[0046] Salts of ursodeoxycholic acid, salts of amide conjugates of
ursodeoxycholic acid, salts of esters of ursodeoxycholic acid, and
salts of esters of amide conjugates of ursodeoxycholic acid, which
may be comprised in the agent of the present invention are not
particularly limited as long as they are pharmaceutically
acceptable salts. Examples of pharmaceutically acceptable salts
include, inorganic salts such as hydrochlorides, hydrobromides,
hydroiodides, nitrates, sulfates, phosphates, etc.; organic acid
salts such as acetates, trifluoroacetates, benzoates, oxalates,
malonates, succinates, maleates, fumarates, tartrates, citrates,
methanesulfonates, ethanesulfonates, trifluoromethanesulfonates,
benzenesulfonates, p-toluenesulfonates, glutamates, aspartates,
etc.; metal salts such as sodium salts, potassium salts, calcium
salts, and magnesium salts, etc.; inorganic salts such as ammonium
salts, etc.; and organic amine salts such as triethylamine salts,
guanidine salts, etc. Examples of pharmaceutically acceptable salts
include preferably sodium salts and potassium salts.
[0047] In the agent of the present invention, ursodeoxycholic acid
or amide conjugates of ursodeoxycholic acid, or esters thereof, or
pharmaceutically acceptable salts thereof may be in the form of
hydrates or solvates.
[0048] The amount of ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof comprised in the agent of the present
invention is not particularly limited and may be selected from a
wide range depending on dosage forms etc.
[0049] For example, the amount of ursodeoxycholic acid or an amide
conjugate of ursodeoxycholic acid, or an ester thereof, or a
pharmaceutically acceptable salt thereof comprised in the agent of
the present invention is 0.00001 to 10% (w/v), preferably 0.0001 to
5% (w/v), more preferably 0.001 to 3% (w/v), even more preferably
0.01 to 2% (w/v), particularly preferably 0.15 to 1.5% (w/v). An
example of the lower limit of the amount is 0.00001% (w/v), a
preferable example is 0.0001% (w/v), a more preferable example is
0.001% (w/v), a further preferable example is 0.01% (w/v), a
particularly preferable example is 0.1% (w/v), a further
particularly preferable example is 0.15% (w/v). An example of the
upper limit of the amount is 10% (w/v), a preferable example is 5%
(w/v), a more preferable example is 3% (w/v), a particularly
preferable example is 2% (w/v), a further particularly preferable
example is 1.5% (w/v). A preferred range of the amount may be
indicated by a combination of the above examples of lower and upper
limits.
[0050] Further, for example, the amount of ursodeoxycholic acid or
an amide conjugate of ursodeoxycholic acid, or an ester thereof, or
a pharmaceutically acceptable salt thereof comprised in the agent
of the present invention is 0.00001 to 10% (w/w), preferably 0.0001
to 5% (w/w), more preferably 0.001 to 3% (w/w), even more
preferably 0.01 to 2% (w/w), particularly preferably 0.15 to 1.5%
(w/w). An example of the lower limit of the amount is 0.00001%
(w/w), a preferable example is 0.0001% (w/w), a more preferable
example is 0.001% (w/w), a further preferable example is 0.01%
(w/w), a particularly preferable example is 0.1% (w/w), and a
further preferable example is 0.15% (w/w). An example of the upper
limit of the amount is 10% (w/w), a preferable example is 5% (w/w),
a more preferable example is 3% (w/w), a particularly preferable
example is 2% (w/w), and a particularly preferable example is 1.5%
(w/w). A preferred range of the amount may be indicated by a
combination of the above examples of lower and upper limits.
[0051] In one embodiment, the amount of ursodeoxycholic acid or an
amide conjugate of ursodeoxycholic acid, or an ester thereof, or a
pharmaceutically acceptable salt thereof comprised in the agent of
the present invention may be 0.3 to 10% (w/w) (e.g., 0.4 to 5%
(w/w), 0.5 to 3% (w/w), 0.6 to 1.5% (w/w), 0.8 to 1.3% (w/w)).
[0052] In the present disclosure, "% (w/v)" means the mass (g) of
the active ingredient (ursodeoxycholic acid and amide conjugate(s)
of ursodeoxycholic acid, and ester(s) thereof, and pharmaceutically
acceptable salt(s) thereof) or an additive (surfactant, etc.)
comprised in 100 mL of an agent. For example, "0.01% (w/v) of
ursodeoxycholic acid" means that the amount of ursodeoxycholic acid
comprised in 100 mL of an agent is 0.01 g.
[0053] In the present disclosure, "% (w/w)" means the mass (g) of
the active ingredient (ursodeoxycholic acid and amide conjugate(s)
of ursodeoxycholic acid, and ester(s) thereof, and pharmaceutically
acceptable salt(s) thereof) or an additive (surfactant, etc.)
comprised in 100 g of an agent. For example, "0.01% (w/w) of
ursodeoxycholic acid" means that the amount of ursodeoxycholic acid
comprised in 100 g of an agent is 0.01 g.
[0054] When ursodeoxycholic acid, an amide conjugate of
ursodeoxycholic acid, an ester of ursodeoxycholic acid, or an ester
of an amide conjugate of ursodeoxycholic acid are in the form of
salt, or in the form of hydrate or solvate (including the form of
hydrate or solvate of the salt), the amount of ursodeoxycholic acid
or an amide conjugate of ursodeoxycholic acid, or an ester thereof,
or a pharmaceutically acceptable salt thereof comprised in the
agent may mean the mass of the salt, hydrate, or solvate (including
the hydrate or solvate of the salt) added into the agent, or may
mean the mass converted as a free form of ursodeoxycholic acid, the
amide conjugate of ursodeoxycholic acid or the ester thereof,
preferably may mean the mass converted as a free form of
ursodeoxycholic acid, the amide conjugate of ursodeoxycholic acid,
or the ester thereof.
[0055] In this disclosure, the term "presbyopia" means a
symptom/disease that is determined to be presbyopia based on
general criteria used by a physician or professional.
[0056] For example, diagnostic criteria for presbyopia include:
[0057] Decreased near vision is noticed as a subjective symptom in
a binocular vision test, and a binocular daily life visual acuity,
which is a binocular distant visual acuity measured under the same
condition as daily life, is less than 0.4 at 40 cm
distance(clinical presbyopia); and/or
[0058] With or without subjective symptoms, under unilateral
best-correction where a corrected visual acuity of one eye is equal
to or more than 1.0 (decimal visual acuity), accommodative
amplitude is less than 2.5 Diopters" (medical presbyopia).
[0059] However, if an accommodometer etc. is not available, a
simple criterion wherein a visual acuity at 40 cm is less than 0.4
may be used.
[0060] In the present disclosure, the term "an eye disease
accompanied by a decrease in lens elasticity" refers to an eye
disease considered in the field of ophthalmology to be accompanied
by a decrease in lens elasticity, including, for example,
presbyopia (e.g., presbyopia due to aging), and a hardening of the
lens induced by drugs and the like.
[0061] In the present disclosure, the term "accommodation function
of the eye" refers to an eye function that automatically focuses on
distant and/or near objects. The term "an eye disease accompanied
by a decrease in accommodative function of the eye" refers to an
eye disease considered in the field of ophthalmology to be
accompanied by a decrease in accommodative function of the eye,
including, for example, presbyopia (e.g., presbyopia due to aging),
and a hardening of the lens induced by drugs etc., and decreased
accommodation function induced by seeing near objects for a long
time.
[0062] The efficacy of the agent of the present invention may be
evaluated, for example, as an increase in "accommodative amplitude
of the eye". The accommodative amplitude of the eye can be measured
as a Diopter (D) which can be determined by the following
expression 1:
Diopter(D)=1/Near Point Distance(m) (Expression 1).
[0063] In general, the accommodative amplitude of the eye is
greater than 10 diopters at 10 years, then gradually decreases to
about 3 diopters at about 45 years and is almost lost at about 60
years. When the accommodative amplitude decreases to about 3
diopters, it becomes difficult to focus on near objects (about 30
cm) in daily life, and subjective symptoms of presbyopia
appear.
[0064] The efficacy of the agent of the present invention may be
evaluated, for example, as an improvement in "visual acuity". The
visual acuity can be measured as near visual acuity (uncorrected
visual acuity, distance-corrected near visual acuity, corrected
visual acuity) and can be measured by using decimal visual acuity,
fractional visual acuity, or logMAR.
[0065] In general, when near visual acuity which is defined to be
measured at about 40 cm decreases to below 0.4, it causes
difficulty in seeing near objects, and subjective symptoms of
presbyopia appear. The agent of the present invention may be used
to improve near visual acuity (e.g., distance-corrected near visual
acuity).
[0066] The agent of the invention may begin to exhibit an efficacy
within one year, preferably within six months, more preferably
within one month, more preferably within one week, and most
preferably within one day after the administration. Further, once
an efficacy is exerted, the efficacy may be exerted continuously
until after one day, preferably until after one week, more
preferably until after one month, more preferably until after six
months, particularly preferably until after one year, and most
preferably until after three years.
[0067] The agent of the present invention may be administered, for
example, so as to increase the accommodative amplitude of the eye
by at least about 0.5 diopters (preferably at least about 1
diopter, more preferably at least about 1.5 diopters, more
preferably at least about 2 diopters, even more preferably at least
about 3 diopters, and still more preferably at least about 4
diopters, particularly preferably at least about 5 diopters, and
still more preferably at least about 10 diopters).
[0068] The agent of the present invention may be administered, for
example, so as to increase distance-corrected near visual acuity
(DCNVA) by at least about 0.5 logMAR (preferably about at least 1.0
logMAR, more preferably about at least 1.5 logMAR, even more
preferably about 2.0 logMAR, even more preferably about 3.0 logMAR,
particularly preferably about 4.0 logMAR, particularly preferably
about 5.0 logMAR, and even more preferably about 6.0 logMAR).
[0069] The term "distance-corrected near visual acuity" generally
refers to near visual acuity measured with distance visual acuity
corrected to 0.0 logMAR (decimal visual acuity of 1.0 or more).
[0070] The agent of the present invention may be administered, for
example, so as to restore the accommodative amplitude of the eye to
at least about 0.5 diopters (preferably at least about 1 diopter,
more preferably at least about 1.5 diopters, more preferably at
least about 2 diopters, more preferably at least about 3 diopters,
particularly preferably at least about 4 diopters, particularly
preferably at least about 5 diopters, and still more preferably at
least about 10 diopters).
[0071] The agent of the present invention may be administered, for
example, so as to restore the distance-corrected near visual acuity
(DCNVA) to at least about 0.5 logMAR (preferably at least about 1.0
logMAR, more preferably at least about 1.5 logMAR, even more
preferably about 2.0 logMAR, even more preferably about 3.0 logMAR,
particularly preferably about 4.0 logMAR, particularly preferably
about 5.0 logMAR, and even more preferably about 6.0 logMAR).
[0072] In the present disclosure, the treatment or prevention of
presbyopia includes increasing an elasticity of the lens, improving
an ability to adjust a thickness of lens, and/or improving an
accommodative function of the eye.
[0073] Although subjective symptoms of presbyopia generally appear
at about 45 years of age as mentioned above, age-related decline in
eye accommodation has been progressing since teens. The agent of
the present invention may be used after the subjective symptoms of
presbyopia appear, and may be used to prevent and/or delay
progression of presbyopia before the subjective symptoms of
presbyopia appear.
[0074] The subjects of administration of the agent of the present
invention are mammals including livestock such as cattle and pigs;
rabbits, monkeys, dogs, cats, and humans, preferably humans.
[0075] In this disclosure, "treatment (treating)" and "prevention
(preventing)" may include, in addition to treating and preventing a
disease, alleviating symptoms of the disease, delaying progression
of the disease, suppressing symptoms of the disease, and inducing
improvement in symptoms of the disease.
[0076] The agent of the present invention may be administered
orally or parenterally (e.g., ocularly, nasally, transdermally,
transmucosally, by injection, etc.). The agent of the present
invention may be prepared in the usual manner in the art by mixing
the active ingredient with, for example, one or more
pharmaceutically acceptable additives, for example, in the form of
oral preparations such as tablets, capsules, granules, powders,
lozenges, syrups, emulsions, suspensions, and the like, or
parenteral preparations such as eye drops, ophthalmic ointments,
injections, suppositories, nasal preparations, and the like.
Preferred formulations of the agent of the present invention
include eye drops (e.g., ophthalmic suspensions) and eye ointments
from the viewpoint of greater efficacy of the agents of the
invention.
[0077] Pharmaceutically acceptable additives that may be comprised
in the agent of the present invention are not particularly limited
and may be selected as appropriate according to the route of
administration, formulation, etc. Examples of such pharmaceutically
acceptable additives include, for example, surfactants, buffers,
tonicity agents, stabilizers, preservatives, antioxidants,
thickeners, solubilizing agents, suspending agents, bases,
solvents, pH adjusters, excipients, disintegrating agents, binders,
fluidizers, lubricants, preservatives, antioxidants, coloring
agents, sweetening agents, and the like.
[0078] When the agent of the present invention is an eye drop,
examples of additives that may be used include surfactants,
buffers, tonicity agents, stabilizers, preservatives, antioxidants,
thickeners, solvents, pH adjusters, and the like.
[0079] Examples of surfactants include cationic surfactants,
anionic surfactants, nonionic surfactants and the like.
[0080] When a surfactant is added to the agent of the present
invention, the amount of the surfactant comprised in the agent may
be appropriately adjusted depending on the type of the surfactant,
etc., and is preferably, for example, 0.01 to 1% (w/v).
[0081] Examples of buffers include phosphoric acid or salts
thereof, which may be hydrates or solvates thereof.
[0082] Examples of the phosphoric acid or salts thereof include
phosphoric acid, trisodium phosphate, sodium dihydrogenphosphate,
sodium hydrogen phosphate (disodium hydrogenphosphate) and the
like, which may be hydrates thereof.
[0083] When a buffer is added to the agent of the present
invention, the amount of the buffer comprised in the agent may be
appropriately adjusted depending on the type of the buffer, etc.,
but for example, 0.001 to 10% (w/v) is preferable, and 0.01 to 5%
(w/v) is more preferable. Two or more kinds of buffers may be used
together.
[0084] Examples of tonicity agents include ionic tonicity agents
and nonionic tonicity agents. Examples of the ionic tonicity agents
include sodium chloride and the like.
[0085] When a tonicity agent is added to the agent of the present
invention, the amount of the tonicity agent comprised in the agent
may be appropriately adjusted according to the type of the tonicity
agent or the like, but for example, 0.001 to 10% (w/v) is
preferable, and 0.01% to 5% (w/v) is more preferable.
[0086] Examples of thickeners include hydroxypropyl methylcellulose
and the like.
[0087] When a thickener is added to the agent of the present
invention, the amount of the thickener may be appropriately
adjusted according to the type of the thickener or the like, but
for example, 0.001 to 5% (w/v) is preferable, and 0.01% to 3% (w/v)
is more preferable.
[0088] When the agent of the present invention is an aqueous
formulation (e.g., eye drops), the pH is preferably 4 to 8 and more
preferably 5 to 7.
[0089] Examples of solvents include water, physiological saline and
the like.
[0090] Examples of the agent of the present invention which is an
aqueous preparation (e.g., eye drop) include aqueous preparations
comprising ursodeoxycholic acid or an amide conjugate of
ursodeoxycholic acid, or an ester thereof, or a pharmaceutically
acceptable salt thereof, water, and an additive selected from ethyl
pyruvate, sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), disodium hydrogenphosphate
(Na.sub.2HPO.sub.4), hydroxypropyl methylcellulose, NaCl, and a
mixture thereof. Here, said "a mixture thereof" means any
combination of the listed specific additives.
[0091] As used herein, the term "an effective amount" is the amount
of the active ingredient required to provide a patient benefit in
the symptoms of a disease.
[0092] A dosage and administration of the agent of the present
invention is not particularly limited as long as the dosage and
administration are sufficient to achieve the desired medicinal
effect, and may be appropriately selected according to the symptoms
of the disease, the age and weight of the patient, the dosage form
of the agent, etc.
[0093] For example, in the case of eye drops, a single dose of 1 to
5 drops (preferably 1 to 3 drops, more preferably 1 to 2 drops,
particularly preferably 1 drop) may be instilled 1 to 4 times per
day (preferably 1 to 3 times per day, more preferably 1 to 2 times
per day, particularly preferably once per day), every day or at an
interval of from one day to one week. The "one drop" is usually
about 0.01 to about 0.1 mL, preferably about 0.015 to about 0.07
mL, more preferably about 0.02 to about 0.05 mL, and particularly
preferably about 0.03 mL.
[0094] In one embodiment, the agent of the present invention have
an immediate effect on presbyopia, an eye disease accompanied by a
decrease in lens elasticity, or an eye disease accompanied by a
decrease in accommodative function of the eye, for example,
compared to EV06.
[0095] The duration of administration of the agent of the present
invention may be determined by a physician or professional.
[0096] In one embodiment, the agent of the present invention may be
an ophthalmic administration agent such as an eye drop (e.g., a
suspension) and an eye ointment, and may be used continuously for
at least 2 days, at least 3 days, at least 7 days, at least 10
days.
[0097] In one embodiment, the agent of the present invention may be
administered at least once (e.g., at least twice, at least three
times) a day.
[0098] In one embodiment, the agent of the present invention, when
administered to the eye, may be less irritating to the eye while
having an effect on presbyopia, an eye disease accompanied by a
decrease in lens elasticity, or an eye disease accompanied by a
decrease in accommodative function of the eye.
EXAMPLES
[0099] The results of pharmacological tests are shown below for a
better understanding of the present invention and are not intended
to limit the scope of the present invention.
[0100] [Pharmacological Test 1]
[0101] The effect of lipoic acid choline ester (EV06) on the lens
elasticity was examined. The tests were conducted with reference to
the methods described in InvestOphthalmol Vis Sci, 57, 2851-2863,
2016. EV06 is a compound represented by the following formula
(2):
##STR00004##
(Preparation of Test Sample)
1) Preparation of Vehicle
[0102] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, and 0.5% (w/v) of NaCl was prepared.
2) Preparation of EVO6 Sample
[0103] EVO6 was sonicated with the addition of the vehicle to
prepare a 5% (w/v) suspension. The resulting 5% (w/v) suspension
was diluted with the vehicle to prepare a 1.5% (w/v) solution.
Further, the resulting 1.5% (w/v) solution was diluted with the
vehicle to prepare a 0.5% (w/v) solution. The total amount of each
sample to be used in one day was prepared before use.
(Test Method)
[0104] 1) Each test sample (2.5 .mu.L/eye) was instilled into the
right eye of 8-month-old C57BL/6J mice with a Pipetman 3 times per
day (around 9:00, 13:00 and 17:00) for 15 to 17 days. [0105] 2)
After the final instillation, the mice were euthanized by carbon
dioxide inhalation, and then the eyeballs were extracted and rinsed
with Hank's balanced salt solution (HBSS). [0106] 3) The sclera
near the optic nerve was cut with a razor, the lens was removed
through the incision, and the removed lens was immersed in HESS.
[0107] 4) The lens was placed on a glass slide, and an all-in-one
fluorescence microscope BZ-9000 (Keyence) was used to capture an
image of the lens (Image a). [0108] 5) Next, one cover glass
(Corning.RTM. 22.times.22 mm Square) was placed on the lens, and an
image in which the thickness of the lens changed due to the weight
was similarly captured (Image b). [0109] 6) A change in the lens
diameter was calculated from Equation 1 wherein the lens diameter
of Image a is subtracted from the lens diameter of Image b, as
described below. Then, the lens elasticity improvement of each
sample group compared with the vehicle control group was calculated
from Equation 2 described below.
[0110] The mean of the vehicle control group was based on 6 eyes
and the mean of each EVO6 sample group was based on 12 eyes.
Change in lens diameter=Lens diameter in Image b of each test
sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each EVO6 sample group-Mean change in lens
diameter of Vehicle control group (Equation 2)
[0111] (Results)
[0112] The results are shown in Table 1.
TABLE-US-00001 TABLE 1 Lens elasticity improvement (.mu.m) 0.5%
EV06 sample 28.8 1.5% EV06 sample 47.3 5% EV06 sample 48.7
[0113] As shown in Table 1, all of the 0.5%, 1.5%, and 5% EVO6
groups showed the increased lens diameter compared with the vehicle
control group, which confirms that EVO6 has an elasticity improving
effect.
[Pharmacological Test 2]
[0114] The effect of sodium ursodeoxycholate on the lens elasticity
was examined.
(Preparation of Test Sample)
1) Preparation of Vehicle
[0115] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
2) Preparation of Sodium Ursodeoxycholate Sample
[0116] Sodium ursodeoxycholate was sonicated with the addition of
the vehicle to prepare a 1.5% (w/v) suspension. The resulting 1.5%
(w/v) suspension was diluted with the vehicle to prepare a 0.5%
(w/v) suspension. Further, the resulting 0.5% (w/v) suspension was
diluted with the vehicle to prepare a 0.15% (w/v) suspension. The
total amount of each sample to be used in one day was prepared
before use.
3) Preparation of EVO6 Sample
[0117] EVO6 was sonicated with the addition of the vehicle to
prepare a 1.5% (w/v) solution. The total amount of the sample to be
used in one day was prepared before use.
(Test Method)
[0118] 1) Each test sample (2.5 .mu.L/eye) was instilled into the
right eye of 8-month-old C57BL/6J mice with a Pipetman 3 times per
day (around 9:00, 13:00 and 17:00) for 12 to 15 days. [0119] 2)
After the final instillation, the mice were euthanized by carbon
dioxide inhalation, and then the eyeballs were extracted and rinsed
with Hank's balanced salt solution (HBSS). [0120] 3) The sclera
near the optic nerve was cut with a razor, the lens was removed
through the incision, and the removed lens was immersed in HBSS.
[0121] 4) The lens was placed on a glass slide, and an all-in-one
fluorescence microscope BZ-9000 (Keyence) was used to capture an
image of the lens (Image a). [0122] 5) Next, one cover glass
(Corning.RTM. 22.times.22 mm Square) was placed on the lens, and an
image in which the thickness of the lens changed due to the weight
was similarly captured (Image b). [0123] 6) A change in the lens
diameter was calculated from Equation 1 wherein the lens diameter
of Image a is subtracted from the lens diameter of Image b, as
described below. Then, the lens elasticity improvement of each
sample group compared with the vehicle control group was calculated
from Equation 2 described below. The mean of the vehicle control
group was based on 5 eyes, the mean of each sodium ursodeoxycholate
sample group was based on 10 eyes, and the mean of the EVO6 sample
group was based on 10 eyes.
[0123] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Vehicle control group (Equation 2)
(Results)
[0124] The results are shown in Table 2.
TABLE-US-00002 TABLE 2 Lens elasticity improvement (.mu.m) 0.15%
sodium 26.5 ursodeoxycholate sample 0.5% sodium 34.8
ursodeoxycholate sample 1.5% sodium 44.7 ursodeoxycholate sample
1.5% EV06 sample 38.2
[0125] As shown in Table 2, all of the 0.15%, 0.5%, and 1.5% sodium
ursodeoxycholate sample groups showed a potent lens elasticity
improving effect. The lens elasticity improving effect of the 1.5%
sample group was stronger than that of EVO6 at the same
concentration.
[Pharmacological Test 3]
[0126] The effect of ursodeoxycholic acid (free form) on the lens
elasticity was examined.
(Preparation of Test Sample)
1) Preparation of Vehicle
[0127] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, and 0.5% (w/v) of NaCl was prepared.
2) Preparation of Ursodeoxycholic Acid Sample
[0128] Ursodeoxycholic acid was sonicated with the addition of the
vehicle to prepare a 1.5% (w/v) suspension. The resulting 1.5%
(w/v) suspension was diluted with the vehicle to prepare a 0.5%
(w/v) suspension. Further, the resulting 0.5% (w/v) suspension was
diluted with the vehicle to prepare a 0.15% (w/v) suspension. The
total amount of each sample to be used in one day was prepared
before use.
3) Preparation of EVO6 Sample
[0129] EVO6 was sonicated with the addition of the vehicle to
prepare a 1.5% (w/v) solution. The total amount of the sample to be
used in one day was prepared before use.
(Test Method)
[0130] 1) Each test sample (2.5 .mu.L/eye) was instilled into the
right eye of 8-month-old C57BL/6J mice with a Pipetman 3 times per
day (around 9:00, 13:00 and 17:00) for 12 to 15 days. [0131] 2)
After the final instillation, the mice were euthanized by carbon
dioxide inhalation, and then the eyeballs were extracted and rinsed
with Hank's balanced salt solution (HESS). [0132] 3) The sclera
near the optic nerve was cut with a razor, the lens was removed
through the incision, and the removed lens was immersed in HESS.
[0133] 4) The lens was placed on a glass slide, and an all-in-one
fluorescence microscope BZ-9000 (Keyence) was used to capture an
image of the lens (Image a). [0134] 5) Next, one cover glass
(Corning.RTM. 22>22 mm Square) was placed on the lens, and an
image in which the thickness of the lens changed due to the weight
was similarly captured (Image b). [0135] 6) A change in the lens
diameter was calculated from Equation 1 wherein the lens diameter
of Image a is subtracted from the lens diameter of Image b, as
described below. Then, the lens elasticity improvement of each
sample group compared with the vehicle control group was calculated
from Equation 2 described below. The mean of the vehicle control
group was based on 5 eyes, the mean of each ursodeoxycholic acid
sample group was based on 10 eyes, and the mean of the EVO6 sample
group was based on 10 eyes.
[0135] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Vehicle control group
(Results)
[0136] The results are shown in Table 3.
TABLE-US-00003 TABLE 3 Lens elasticity improvement (.mu.m) 0.15%
ursodeoxycholic 31.8 acid sample 0.5% ursodeoxycholic 39.4 acid
sample 1.5% ursodeoxycholic 59.9 acid sample 1.5% EV06 sample
42.5
[0137] As shown in Table 3, all of the 0.15%, 0.5%, and 1.5% sodium
ursodeoxycholate sample groups showed a potent lens elasticity
improving effect. The lens elasticity improving effect of the 1.5%
sample group was stronger than that of EVO6 at the same
concentration.
[Pharmacological Test 4]
[0138] The effect of once-daily instillation of ursodeoxycholic
acid for 2 weeks on the lens elasticity was examined.
(Preparation of Test Sample)
1) Preparation of Vehicle
[0139] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
2) Preparation of Ursodeoxycholic Acid Sample
[0140] Ursodeoxycholic acid was sonicated with the addition of the
vehicle to prepare a 3.0% (w/v) suspension. The resulting 3.0%
(w/v) suspension was diluted with the vehicle to prepare a 1.0%
(w/v) suspension. Further, the resulting 1.0% (w/v) suspension was
diluted with the vehicle to prepare a 0.3% (w/v) suspension. The
total amount of each sample to be used in one day was prepared
before use.
3) Preparation of EVO6 Sample
[0141] EVO6 was sonicated with the addition of the vehicle to
prepare a 1.5% (w/v) solution. The total amount of the sample to be
used in one day was prepared before use.
(Test method) [0142] 1) Each test sample (2.5 .mu.L/eye) was
instilled into the right eye of 8-month-old C57BL/6J mice with a
Pipetman once per day (QD; around 9:00), twice per day (BID; around
9:00 and 17:00), or 3 times per day (TID; around 9:00, 13:00 and
17:00) for 14 days. [0143] 2) After the final instillation, the
mice were euthanized by carbon dioxide inhalation, and then the
eyeballs were extracted and rinsed with Hank's balanced salt
solution (HBSS). [0144] 3) The sclera near the optic nerve was cut
with a razor, the lens was removed through the incision, and the
removed lens was immersed in HBSS. [0145] 4) The lens was placed on
a glass slide, and an all-in-one fluorescence microscope BZ-9000
(Keyence) was used to capture an image of the lens (Image a).
[0146] 5) Next, one cover glass (Corning.RTM. 22.times.22 mm
Square) was placed on the lens, and an image in which the thickness
of the lens changed due to the weight was similarly captured (Image
b). [0147] 6) A change in the lens diameter was calculated from
Equation 1 wherein the lens diameter of Image a is subtracted from
the lens diameter of Image b, as described below. Then, the lens
elasticity improvement of each sample group compared with the
vehicle control group was calculated from Equation 2 described
below. The mean of the vehicle control group was based on 5 eyes,
the mean of each ursodeoxycholic acid sample group was based on 10
eyes, and the mean of each EVO6 sample group was based on 10
eyes.
[0147] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Vehicle control group
(Results)
[0148] The results are shown in Table 4.
TABLE-US-00004 TABLE 4 Lens improvement elasticity (.mu.m) 0.3%
ursodeoxycholic acid sample 2.8 (QD) 1% ursodeoxycholic acid sample
28.1 (QD) 3% ursodeoxycholic acid sample 30.4 (QD) 1.5% EV06 sample
(QD) -3.6 1.5% EV06 sample(BID) 15.7 1.5% EV06 sample(TID) 29.5
[0149] As shown in Table 4, 1% ursodeoxycholic acid sample and 3%
ursodeoxycholic acid sample caused a potent lens elasticity
improvement when they were instilled once-daily while 1.5% EVO6
sample instilled once-daily had no effect, which indicates that
ursodeoxycholic acid has a more potent lens elasticity improvement
effect compared with EV06.
[Pharmacological Test 5]
[0150] The effect of 1% ursodeoxycholic acid instilled once-daily
for 1, 3, 7, 10, or 14 days on the lens elasticity was
examined.
(Preparation of Test Sample)
1) Preparation of Vehicle
[0151] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
2) Preparation of 1% ursodeoxycholic acid sample
[0152] Ursodeoxycholic acid was sonicated with the addition of the
vehicle to prepare a 1.0% (w/v) suspension. The total amount of the
sample to be used in one day was prepared before use.
(Test Method)
[0153] 1) The test sample (2.5 pL/eye) was instilled into both eyes
of 8-month-old C57BL/6J mice with a Pipetman once per day (QD;
around 13:30) for 1, 3, 7, 10, or 14 days. [0154] 2) Twenty-four
hours after the final instillation, the mice were euthanized by
carbon dioxide inhalation, and then the eyeballs were extracted and
rinsed with Hank's balanced salt solution (HBSS). [0155] 3) The
sclera near the optic nerve was cut with a razor, the lens was
removed through the incision, and the removed lens was immersed in
HBSS. [0156] 4) The lens was placed on a glass slide, and an
all-in-one fluorescence microscope BZ-9000 (Keyence) was used to
capture an image of the lens (Image a). [0157] 5) Next, one cover
glass (Corning.RTM. 22>22 mm Square) was placed on the lens, and
an image in which the thickness of the lens changed due to the
weight was similarly captured (Image b). [0158] 6) A change in the
lens diameter was calculated from Equation 1 wherein the lens
diameter of Image a is subtracted from the lens diameter of Image
b, as described below. Then, the lens elasticity improvement of
each sample group compared with the vehicle control group was
calculated from Equation 2 described below. Each mean of the
untreated group and each ursodeoxycholic acid sample group was
based on 9 or 10 eyes.
[0158] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Untreated group (Equation 2)
(Results)
[0159] The results are shown in Table 5.
TABLE-US-00005 TABLE 5 Lens elasticity improvement (.mu.m) 1%
ursodeoxycholic acid sample 9.6 (1 day) 1% ursodeoxycholic acid
sample 21.1 (3 days) 1% ursodeoxycholic acid sample 27.4 (7 days)
1% ursodeoxycholic acid sample 38.1 (10 days) 1% ursodeoxycholic
acid sample 34.2 (14 days)
[0160] As shown in Table 5, the 1% ursodeoxycholic acid sample
instilled once-daily caused improvement in the lens elasticity
according to the increase of the duration of instillation, and
showed definitely an improvement in lens elasticity after
instillation for 3 days. This suggests that ursodeoxycholic acid
can early cause the effect.
[Pharmacological Test 6]
[0161] The effect of once-daily instillation of ursodeoxycholic
acid methyl ester for 7 days on the lens elasticity was
examined.
(Preparation of Test Sample)
1) Preparation of Vehicle
[0162] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
2) Preparation of Ursodeoxycholic Acid Methyl Ester Sample
[0163] Ursodeoxycholic acid methyl ester was sonicated with the
addition of the vehicle to prepare a 0.3% (w/v) suspension, a 1.0%
(w/v) suspension and a 3.0% (w/v) suspension. The total amount of
each sample to be used in one day was prepared before use.
(Test Method)
[0164] 1) Each test sample (2.5 .mu.L/eye) was instilled into both
eyes of 7-month-old C57BL/6J mice with a Pipetman once per day (QD;
around 13:30) for 7 days. [0165] 2) Twenty-four hours after the
final instillation, the mice were euthanized by carbon dioxide
inhalation, and then the eyeballs were extracted and rinsed with
Hank's balanced salt solution (HBSS). [0166] 3) The sclera near the
optic nerve was cut with a razor, the lens was removed through the
incision, and the removed lens was immersed in HBSS. [0167] 4) The
lens was placed on a glass slide, and an all-in-one fluorescence
microscope BZ-9000 (Keyence) was used to capture an image of the
lens (Image a). [0168] 5) Next, one cover glass (Corning.RTM.
22.times.22 mm Square) was placed on the lens, and an image in
which the thickness of the lens changed due to the weight was
similarly captured (Image b). [0169] 6) A change in the lens
diameter was calculated from Equation 1 wherein the lens diameter
of Image a is subtracted from the lens diameter of Image b, as
described below. Then, the lens elasticity improvement of each
sample group compared with the vehicle control group was calculated
from Equation 2 described below. Each mean of the vehicle control
group and each ursodeoxycholic acid methyl ester sample group was
based on 9 or 10 eyes.
[0169] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Vehicle control group (Equation 2)
(Results)
[0170] The results are shown in Table 6.
TABLE-US-00006 TABLE 6 Lens elasticity improvement (.mu.m) 0.3%
ursodeoxycholic acid 13.2 methyl ester sample 1% ursodeoxycholic
acid 33.0 methyl ester sample 3% ursodeoxycholic acid 46.5 methyl
ester sample
[0171] As shown in Table 6, 1% ursodeoxycholic acid methyl ester
sample and 3% ursodeoxycholic acid methyl ester sample caused a
potent lens elasticity improvement even when they were instilled
once-daily. These results suggest that ursodeoxycholic acid methyl
ester may also have a more potent lens elasticity improvement
effect compared with 1.5% EV06.
[Pharmacological Test 7]
[0172] The effect of tauroursodeoxycholic acid instilled once-daily
for 7 days on the lens elasticity was examined.
(Preparation of Test Sample)
1) Preparation of Vehicle
[0173] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
2) Preparation of Tauroursodeoxycholic Acid Sample
[0174] Tauroursodeoxycholic acid was dissolved with the addition of
the vehicle to prepare a 1.0% (w/v) solution. The total amount of
each sample to be used in one day was prepared before use.
(Test Method)
[0175] 1) Each test sample (2.5 .mu.L/eye) was instilled into both
eyes of 7-month-old C57BL/6J mice with a Pipetman once per day (QD;
around 13:30) for 7 days. [0176] 2) Twenty-four hours after the
final instillation, the mice were euthanized by carbon dioxide
inhalation, and then the eyeballs were extracted and rinsed with
Hank's balanced salt solution (HBSS). [0177] 3) The sclera near the
optic nerve was cut with a razor, the lens was removed through the
incision, and the removed lens was immersed in HBSS. [0178] 4) The
lens was placed on a glass slide, and an all-in-one fluorescence
microscope BZ-9000 (Keyence) was used to capture an image of the
lens (Image a). [0179] 5) Next, one cover glass (Corning
(registered trade mark) 22.times.22 mm Square) was placed on the
lens, and an image in which the thickness of the lens changed due
to the weight was similarly captured (Image b). [0180] 6) A change
in the lens diameter was calculated from Equation 1 wherein the
lens diameter of Image a is subtracted from the lens diameter of
Image b, as described below. Then, the lens elasticity improvement
of each sample group compared with the vehicle control group was
calculated from Equation 2 described below. Each mean of the
vehicle control group and the tauroursodeoxycholic acid sample
group was based on 10 eyes.
[0180] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Vehicle control group (Equation 2)
(Results)
[0181] The results are shown in Table 7.
TABLE-US-00007 TABLE 7 Lens elasticity improvement (.mu.m) 1%
tauroursodeoxycholic 29.7 acid sample
[0182] The 1% tauroursodeoxycholic acid sample instilled once-daily
caused a potent lens elasticity improvement as shown in Table 7
while the 1.5% EVO6 sample instilled once-daily for 14 days had no
effect as shown in Table 4, which suggests that
tauroursodeoxycholic acid has a more potent lens elasticity
improvement effect than EV06.
[Pharmacological Test 8]
[0183] The effect of glycoursodeoxycholic acid instilled once-daily
for 7 days on the lens elasticity was examined.
(Preparation of Test Sample)
1)Preparation of Vehicle
[0184] A vehicle comprising 0.1% (w/v) of ethyl pyruvate, 0.269%
(w/v) of sodium dihydrogenphosphate monohydrate
(NaH.sub.2PO.sub.4H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
2)Preparation of Glycoursodeoxycholic Acid Sample
[0185] Glycoursodeoxycholic acid was sonicated with the addition of
the vehicle to prepare a 1.0% (w/v) suspension.
[0186] The total amount of each sample to be used in one day was
prepared before use.
(Test Method)
[0187] 1) Each test sample (2.5 .mu.L/eye) was instilled into both
eyes of 8-month-old C57BL/6J mice with a Pipetman once per day (QD;
around 13:30) for 7 days. [0188] 2) Twenty-four hours after the
final instillation, the mice were euthanized by carbon dioxide
inhalation, and then the eyeballs were extracted and rinsed with
Hank's balanced salt solution (HBSS). [0189] 3) The sclera near the
optic nerve was cut with a razor, the lens was removed through the
incision, and the removed lens was immersed in HESS. [0190] 4) The
lens was placed on a glass slide, and an all-in-one fluorescence
microscope BZ-9000 (Keyence) was used to capture an image of the
lens (Image a). [0191] 5) Next, one cover glass.RTM. 22.times.22 mm
Square) was placed on the lens, and an image in which the thickness
of the lens changed due to the weight was similarly captured (Image
b). [0192] 6) A change in the lens diameter was calculated from
Equation 1 wherein the lens diameter of Image a is subtracted from
the lens diameter of Image b, as described below. Then, the lens
elasticity improvement of each sample group compared with the
vehicle control group was calculated from Equation 2 described
below. Each mean of the vehicle control group and the
glycoursodeoxycholic acid sample group was based on 9 to 10
eyes.
[0192] Change in lens diameter=Lens diameter in Image b of each
test sample-Lens diameter in Image a of each test sample (Equation
1)
Lens elasticity improvement of each sample group=Mean change in
lens diameter of each Test sample group-Mean change in lens
diameter of Vehicle control group (Equation 2)
(Results)
[0193] The results are shown in Table 8.
TABLE-US-00008 TABLE 8 Lens elasticity improvement (.mu.m) 1%
glycoursodeoxycholic 20.1 acid sample
[0194] The 1% glycoursodeoxycholic acid sample instilled once-daily
caused a potent lens elasticity improvement as shown in Table 8
while the 1.5% EVO6 sample instilled once-daily for 14 days had no
effect as shown in Table 4, which suggests that
glycoursodeoxycholic acid has a more potent lens elasticity
improvement effect than EV06.
[Ocular Irritation Test]
(Preparation of Sample)
[0195] A vehicle (aqueous solution) comprising 0.1% (w/v) of ethyl
pyruvate, 0.269% (w/v) of sodium dihydrogenphosphate-monohydrate
(NaH.sub.2PO.sub.4.H.sub.2O), 0.433% (w/v) of disodium
hydrogenphosphate (Na.sub.2HPO.sub.4), 0.2% (w/v) of hydroxypropyl
methylcellulose, 0.5% (w/v) of NaCl was prepared.
(Test Method)
[0196] Group treated with an ophthalmic suspension of
ursodeoxycholic acid 1% (w/v), 3% (w/v), and 10% (w/v)
ursodeoxycholic acid ophthalmic suspensions were prepared in the
same manner as in the above pharmacological tests. These ophthalmic
suspensions and the vehicle were each instilled into the left eye
of Japanese White rabbits at a dose of 50 .mu.L/eye with pipette
twice per day at a 6-hour interval for 2 weeks. One hour after the
final instillation, ocular irritation of anterior segment of the
eye was evaluated according to the McDonald-Shadduck method, and
the lens was observed. The contralateral eye was untreated. The
ocular irritation of anterior segment of the eye was scored
according to the following criteria: +1: mild; +2: moderate; +3:
severe.
(Test Result)
[0197] The test results are shown in Table 9. After the 2
week-repeated instillation, no abnormal findings were observed in
eyes treated with the ophthalmic suspensions of ursodeoxycholic
acid in the observation of ocular irritation of anterior segment of
the eye and lens observation. Histopathological examination of the
eyes showed no abnormal findings.
TABLE-US-00009 TABLE 9 1% Urso- 3% Urso- 10% Urso- deoxy- deoxy-
deoxy- Ophthalmic cholic cholic cholic suspension Vehicle acid acid
acid Number of animals 3 3 3 3 Ocular Conjunctival -- -- -- --
irritation hyperemia of anterior Palpebral -- -- -- -- segment of
conjunctival the eye .sup.1) edema Discharge -- -- -- -- Corneal --
-- -- -- opacity Corneal -- -- -- -- epithelial disorder Lens -- --
-- -- Histopathological -- -- -- -- examination --: No noteworthy
findings, .sup.1) Score of the instilled left eye and the number of
the eye, 1 hour after the final instillation are described.
(Discussion)
[0198] It is shown that the ophthalmic suspensions of
ursodeoxycholic acid is highly safe.
INDUSTRIAL APPLICABILITY
[0199] The agent of the present invention is useful for treating or
preventing eye diseases such as presbyopia etc.
* * * * *